<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078908</url>
  </required_header>
  <id_info>
    <org_study_id>JBR-1-2013</org_study_id>
    <secondary_id>2013-002211-10</secondary_id>
    <nct_id>NCT02078908</nct_id>
  </id_info>
  <brief_title>The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study</brief_title>
  <official_title>The Effect of Sodium Nitrite on Renal Variables, Brachial and Central Blood Pressure in Healthy Humans. A Randomized, Cross Over, Placebo Controlled Dose-response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of different doses of sodium nitrite&#xD;
      infusion in 12 healthy subjects. The effects on renal handling of nitrite, nitrate, sodium&#xD;
      and water, plasma concentrations of vasoactive hormones, peripheral (brachial) and central&#xD;
      blood pressure will be evaluated.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Sodium nitrite infusion&#xD;
&#xD;
        1. increases urinary sodium excretion and renal filtration rate&#xD;
&#xD;
        2. lowers blood pressure, central as well as peripheral&#xD;
&#xD;
        3. affects vasoactive hormones&#xD;
&#xD;
        4. it is possible to establish a dose that affects the renal function with only minor&#xD;
           effect on the blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Nitric oxide (NO) is an important vasodilating molecule with a very complex biochemistry and&#xD;
      metabolism. NO is classically synthesized from L-arginin by endothelial nitric oxide synthase&#xD;
      (eNOS) located in the endothelial cell lining. Several chronic cardiovascular diseases such&#xD;
      as hypertension, chronic kidney disease and diabetes are accompanied by endothelial&#xD;
      dysfunction and hence diminished synthesis of NO. NO is a very reactive molecule and direct&#xD;
      investigation of its function are limited and it has mainly been investigated by inhibition&#xD;
      of eNOS. Recent research has shown that sodium nitrite is readily converted to NO by enzymes&#xD;
      in vivo. The effects of sodium nitrite on renal variables, vasoactive hormones and central&#xD;
      blood pressure are previously unexamined. It is now possible to achieve serial estimations of&#xD;
      the central aortic systolic pressure (CASP) by newly designed wrist born device.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        1. Sodium nitrite infusion increases the urinary sodium excretion and glomerular filtration&#xD;
           rate (GFR) in a dose related manner.&#xD;
&#xD;
        2. Sodium nitrite infusion increases plasma levels of nitrite, nitrate, NO and cyclic&#xD;
           guanosine monophosphate (cGMP)&#xD;
&#xD;
        3. Sodium nitrite infusion lowers the peripheral and central blood pressure&#xD;
&#xD;
        4. Renal clearance of nitrite is constant and not dose dependent&#xD;
&#xD;
        5. Sodium nitrite infusion affects vasoactive hormones&#xD;
&#xD;
        6. It is possible to establish a dose that affects the renal variables with only minor&#xD;
           effect on the blood pressure.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The purpose of this study is to investigate the effects of sodium nitrite infusion on&#xD;
&#xD;
        1. Renal handling of nitrite, nitrate, sodium and water&#xD;
&#xD;
        2. Plasma concentrations of vasoactive hormones&#xD;
&#xD;
        3. Peripheral (brachial) blood pressure and CASP&#xD;
&#xD;
      Design:&#xD;
&#xD;
      12 healthy subjects are recruited in this randomised, cross over, placebo controlled,&#xD;
      single-blinded study. Each subject will attend to four examination days. Four days prior to&#xD;
      each examination day subjects are given a standardized diet with a low level of nitrate and&#xD;
      nitrite. On the evening before the examination day the subjects take a single dose of lithium&#xD;
      carbonate 300 mg in order to measure lithium clearance. On the examination days subjects are&#xD;
      receiving a two hour infusion of either placebo (isotonic sodium chloride) or one of three&#xD;
      doses of sodium nitrite. During the four examination days each subject receives all&#xD;
      treatments in random order.&#xD;
&#xD;
      Perspectives:&#xD;
&#xD;
      Knowledge regarding hemodynamic and renal dose-response relationship is essential, in order&#xD;
      to carry out future planned studies of the nitrite-NO system, in hypertensive subjects and&#xD;
      during simultaneous modulation of various enzyme systems, involved in the conversion of&#xD;
      nitrite to NO. Increasing knowledge about the nitrite-NO system can contribute to changing&#xD;
      the clinical practise of diagnostics and treatment of cardiovascular diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional urinary sodium excretion</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nitrite clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>One day</time_frame>
    <description>Measured by determent renal clearance of 51Cr-EDTA (51-chrome ethylenediaminetetraacetic acid) using constant infusing technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal sodium transport</measure>
    <time_frame>One day</time_frame>
    <description>Proximal sodium transport is estimated by lithium clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free water clearance</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of epithelial sodium channels (ENaC)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of water channels (aquaporin-2)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of renin</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of angiotensin 2</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of aldosterone</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of atrial natriuretic peptide (ANP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of brain natriuretic peptide (BNP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of endothelin</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of vasopressin (AVP, ADH)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral (brachial) blood pressure</measure>
    <time_frame>One day</time_frame>
    <description>Measured by oscillometric sphygmomanometer, Omron 705IT, Omron Matsusaka CO. Ltd.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic systolic blood pressure (CASP)</measure>
    <time_frame>One day</time_frame>
    <description>Estimated by tonometric pulse wave analysis. Device: BPro from HealthSTATS International, Singapore</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>40 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 micrograms sodium nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous 2 hour infusion of sodium chloride, 25 ml/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 40 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour</description>
    <arm_group_label>40 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 120 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour</description>
    <arm_group_label>120 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite, 240 micrograms/kg/hour</intervention_name>
    <description>Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour</description>
    <arm_group_label>240 micrograms sodium nitrite</arm_group_label>
    <other_name>NaNO2</other_name>
    <other_name>ATC V03AB08</other_name>
    <other_name>EV substance code: SUB15308MIG</other_name>
    <other_name>CAS15 number: 7632-00-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continuous 2 hour infusion of sodium chloride, 25 ml/hour</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18,5-30 kg/m2&#xD;
&#xD;
          -  Women must use safe contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tobacco smoking, medicine or substance abuse&#xD;
&#xD;
          -  Weekly consumption of more than 21 standard drinks of alcohol for men and 14 standard&#xD;
             drinks of alcohol for women (1 danish standard drink equals 12 grams of alcohol)&#xD;
&#xD;
          -  Medical treatment in the last 2 weeks except for contraception&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) &lt; 60 ml/min&#xD;
&#xD;
          -  neoplasm&#xD;
&#xD;
          -  clinically significant heart, lung, liver, kidney, metabolic og neurologic disease&#xD;
&#xD;
          -  clinically significant findings in screening blood samples, urine sample or ECG&#xD;
&#xD;
          -  Office blood pressure &gt; 140/90 mmHg&#xD;
&#xD;
          -  Blood donation within 1 month of the first day of investigation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical Research, Regional Hospital Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Chief physician, PhD</investigator_title>
  </responsible_party>
  <keyword>Central blood pressure</keyword>
  <keyword>Peripheral (brachial) blood pressure</keyword>
  <keyword>Renal variables</keyword>
  <keyword>Vasoactive hormones</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

